Anivive sells dog lymphoma drug to Dechra Pharma
by Katie Pfaff
Dechra Pharmaceuticals PLC, has acquired a canine lymphoma drug from Pet health tech firm, Anivive Lifesciences. The therapy, Laverdia™-CA1 (verdinexor), is the first of its kind, according to the company.
Laverdia-CA1 is given as a tablet to treat lymphoma in dogs, and can be given at home. The therapy will be sold in the first quarter of 2022. Regulatory approval is pending in the EU, UK, Australia, Brazil, Canada, and Japan.
“We are delighted to acquire the worldwide rights to Laverdia,” said Ian Page, chief executive officer at Dechra. “Its addition to our portfolio will expand Dechra into a new, niche therapy area, while also offering veterinarians and dog owners a simple to use, effective medication for lymphoma that extends the time a family has with their pet.”
With licensure of Laverdia-CA1, Anivive will continue R&D of more new therapies currently in its pipeline, including biologics, vaccines, and additional novel pharmaceuticals, according to the company. Among its endeavors, Anivive is working with a first-of-its-kind vaccine for systemic fungal disease, including Valley Fever.
"Our team is excited to focus on the accelerated development of additional novel therapeutics that give veterinarians new treatment options for their most challenging cases," said David Bruyette, DVM, DACVIM, chief medical officer at Anivive. "We remain committed, as well, to industry education and knowledge-sharing that increases awareness and use of new technology in the veterinary profession."
Comments
Related Articles
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment